T ryptase 1 is a mast cell (MC) restricted serine protease stored in abundance in the secretory granules, as an enzymatically active tetramer ionically bound to serglycin proteoglycan. The serum tryptase level is normally Ͻ1 ng/mL, but it increases in patients with systemic anaphylaxis and other inflammatory disorders when their tissue MCs become activated. 2 Mouse MC protease 6 (mMCP-6) is the ortholog of human tryptase. 3 Tryptases have pathophysiologic functions pertinent to the development of abdominal aortic aneurysms (AAAs). Tryptase induces vascular leakage 4 and chemotaxis of eosinophils and neutrophils. 5, 6 In support of these data, the injection of recombinant mMCP-6 in the mouse's peritoneal cavity or lungs results in a marked infiltration of granulocytes at those tissue sites. 7, 8 Moreover, mMCP-6 -null (Mcpt6 Ϫ/Ϫ ) mice have a diminished ability to combat bacteria and helminth infections because of a defect in the rapid recruitment of granulocytes to infected tissue sites. 7, 9 Mouse and human tryptases induce endothelial cells (ECs) and other cell types to increase their expression of numerous chemokines (eg, interleukin [IL]-8) and cytokines (eg, IL-1␤) 10 by unknown mechanisms. Mouse and human tryptases also activate protease zymogens (eg, promatrix metalloproteinase-3 [pro-MMP-3] 11 and prourokinase 12 ) that have been implicated in AAA formation. 13, 14 In turn, these tryptase-activated proteases can trigger a more ex-tensive proenzyme activation cascade 11 that likely contributes to arterial wall remodeling.
MCs are numerous in the media 15 and adventitia 16 of human or murine AAA lesions. They often localize adjacent to the thrombosed vessels and neovessels, 15, 17 and release factors that promote thrombolysis, prevent coagulation, and enhance neovessel growth. 17, 18 The absence of MCs protects mice and rats from experimental AAA formation, 16, 18 and the pharmacological activation or stabilization of MCs can differentially alter AAA growth in mice. 18 In addition to recruiting leukocytes and activating proenzymes, tryptase can act as an autocrine mediator, provoking the release of histamine and other mediators from nearby MCs. 19, 20 Thus, tryptase and its mouse ortholog mMCP-6 might be important MC-derived effectors in AAA pathogenesis. We now report that the tryptase levels in the serum of AAA patients associate with aortic expansion. Using Mcpt6 Ϫ/Ϫ mice, we also show that this tryptase participates in experimental AAA formation in vivo.
Methods
See the Online Data Supplement at http://circres.ahajournals.org for details.
Tryptase Detection in AAA Lesions
Paraffin-embedded human aortic sections were prepared from 10 AAA donors (5 females and 5 males; mean age, 78.80Ϯ2.05 years) and 10 non-AAA heart-transplant patients (5 females and 5 males; mean age, 41.90Ϯ4.19 years) without detectable vascular diseases, from the Department of Surgery, Washington University in St. Louis. These sections were evaluated for the presence of tryptase protein (mouse antihuman tryptase monoclonal antibody, 1:1500, Chemicon International, Inc., Billerica, MA) and elastin fiber (Verhoeff-Van Gieson staining). Human aortic tissue extracts were prepared from 3 female AAA patients and 3 female heart-transplant donors with no detectable vascular disease from the Department of Medicine, Brigham and Women's Hospital. Lysates of the resulting tissue samples were used for immunoblot analysis (30 g/lane) with the same tryptase antibody (1:1000). The same protein blot was reprobed using a ␤-actin antibody (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA) to affirm equal protein loading. Separate human protocols were preapproved by the Human Investigation Review Committees at Washington University in St. Louis and at Brigham and Women's Hospital.
Results

Association of Serum Tryptase Level With Aneurysmal Progression
MC degranulation and inflammatory mediator release associate with murine AAA formation. 18 We hypothesized that patients with AAA have elevated serum MC tryptase levels. To test this hypothesis, we developed an enzyme-linked immunosorbent assay to measure human serum tryptase levels. In this study, cases of AAA and controls are from the Viborg Study-a population-based randomized screening trial of men 65 to 73 years of age. 21 Of the patients in this study, 100 had defined AAA, and 35 age-matched men did not. Characteristics of cases and controls are listed in Tables  1 and 2 . Controls had a maximal diameter below 25 mm, with an average of 17 mm, as the background population. In comparison with controls, AAA patients had more coexisting atherosclerotic manifestations, including previous acute myocardial infarction and angina pectoris. AAA patients also had lower ankle-brachial blood pressure indices, more frequent smoking, higher body mass index (BMI), and lower pulmonary function than did control subjects. Serum tryptase levels (ng/mL) had a left-skewed distribution in these populations, and were therefore log-transformed. The mean transformed serum tryptase levels of the AAA group and the control group, and those with and without coexisting cardiovascular and pulmonary diseases, were compared by the Student t test. The mean log-transformed serum tryptase levels in men with and without AAA were 1.80Ϯ0.35 and 1.69Ϯ0.20 (mean Ϯ SD, ng/mL), respectively (Pϭ0.041) ( levels in the control group may be due to the high percentage of current smokers (42.9%), and because many in the control group had acute myocardial infarction, angina pectoris, stroke, or hypertension (total 25.7%), although these subjects did not have AAA (Tables 1 and 2 ). Patients with coexisting cardiovascular and pulmonary diseases, however, had levels of mean log-transformed serum tryptase similar to those without coexisting cardiovascular and pulmonary diseases (1.78Ϯ0.37 ng/mL versus 1.76Ϯ0.26 ng/mL, Pϭ0.714). Elevated serum tryptase levels in AAA patients suggest an association of this MC protease with AAA development. We performed a Pearson correlation analysis to test whether serum tryptase levels associate with initial AAA size at baseline or the mean annual expansion rate. Initial AAA size and tryptase levels correlated weakly and insignificantly (rϭ0.14, Pϭ0.106). The mean annual expansion rate also correlated weakly, but significantly, with serum tryptase levels (rϭ0.30, Pϭ0.003) ( Figure 1A ). These findings did not change after adjustment for other potential AAA risk factors, including AAA size, use of glucocorticoids, BMI, diastolic blood pressure, use of low-dose aspirin, current smoking, lowest ankle-brachial blood pressure index, coexisting cardiovascular and pulmonary diseases, age, and aneurysm wall calcification of more or less than 50% of the circumference 22 at the maximal diameter. Serum tryptase levels still associated weakly and insignificantly with initial AAA size (rϭ0.12, Pϭ0.299), but significantly with AAA expansion rate (rϭ0.29, Pϭ0.005).
Because of our relatively small sample sizes, we classified serum tryptase levels into tertiles and performed Cox regression analysis to assess whether serum tryptase levels associated with subsequent AAA surgical repair or overall mortality. The crude relative risk for later surgical repair increased 1.74 based on the median, quartiles, or quintiles, the significant association between serum tryptase levels and the need for later repair persisted: median (HR, 1.94; 95% CI, 1.001-3.741, Pϭ0.049), quartiles (HR, 1.43; 95% CI, 1.07-1.94, Pϭ0.017), and quintiles (HR, 1.39; 95% C.I., 1.09 -1.765, Pϭ0.008). We also found that serum tryptase levels correlated with overall mortality in this population, although less profoundly. The crude relative risk for dying increased 43% between the tertiles (HR, 1.43; 95% CI, 0.98 -2.10, Pϭ0.065), but further increased to more than 3 times between the tertiles (HR, 3.17; 95% C.,1.60 -6.30, Pϭ0.001) after adjustment for the mentioned potential AAA risk factors (Table 4) .
Increased Tryptase Expression in Human AAA Lesions
Significantly higher serum tryptase levels in AAA patients, in comparison with non-AAA subjects, suggested that AAA lesions might have higher tryptase expression than normal aortas. Immunostaining of aortic sections from AAA lesions and from non-AAA donors showed high tryptase immunoreactivity in the adventitia and media (as determined by Verhoeff-Van Gieson elastin staining) of human AAA lesions. The adventitia of healthy aortas contained only a few tryptase-positive MCs ( Figure 1B ). Immunoblot analysis of aortic tissue extracts revealed similar tryptase expression patterns. AAA tissue extracts contained more of the 30-kDa human tryptase than those prepared from normal aortas ( Figure 1C ). These observations agree with the elevated serum tryptase levels in AAA patients and their significant correlations with subsequent AAA surgery (Table 3) or death (Table 4) .
Tryptase Deficiency Reduced AAA Formation in Mice
As discussed, tryptases trigger MC activation, stimulate inflammatory cell infiltration, and activate AAA-pertinent proteases, compatible with their participation in AAA formation. Experiments in mice subjected to aortic elastase perfusion showed increased expression of mMCP-6 and an essential role of this MC tryptase in AAA development. At 14 days postperfusion, all wild-type [WT] mice developed AAA, but no Mcpt6 Ϫ/Ϫ mice did. Aortic sections from healthy mice or those from Mcpt6 Ϫ/Ϫ mice 14 days postperfusion, immunostained with a rabbit anti-mMCP-6 polyclonal antibody, 9, 23 showed no mMCP-6 protein. The same antibody, however, detected mMCP-6 expression in both the media and adventitia in aortic sections from WT mice 14 days post-elastase perfusion ( Figure 1D ) as in human AAA lesions ( Figure 1B) . Tryptase mMCP-6-positive mast cells in the media in aortic sections from WT mice were further confirmed with antimouse c-Kit (CD117) monoclonal antibody-mediated immunostaining (data not shown). We extended the time point to 56 days. Aortic expansion increased by Ͼ150% in WT mice, but the aortas of Mcpt6 Ϫ/Ϫ mice showed less ectasia ( Figure  2A ). In comparison with WT mice, at 7 days, 14 days, and 56 days, Mcpt6 Ϫ/Ϫ mice had significantly reduced AAA lesion accumulation of macrophages ( Figure 2B ) and T cells ( Figure  2C ). Lesions of Mcpt6 Ϫ/Ϫ mice contained more media smooth-muscle cells (SMC) than those of WT mice at the 7-day time point (Figure 2D ). Reduced inflammatory cell numbers correlated with low MHC class II-positive areas in Mcpt6 Ϫ/Ϫ mouse lesions at all 3 time points ( Figure 2E ). Thus, tryptase deficiency impaired inflammatory cell accumulation in AAA lesions. This conclusion agrees with the B indicates unstandardized regression coefficient; SE, standard error of B; Wald, Wald test significance value; df, degrees of freedom; Sig, the significance value of the coefficient; Exp(B), the predicted change in the hazard for each unit increase in the covariate; CI, confidence interval; MAPD, maximal aneurysmal anteroposterior diameter; Abi, ankle-brachial blood pressure index (sensitive marker for coexisting lower limb atherosclerosis); Coex, hospital-recorded coexisting hypertension, pulmonary obstructive disease, and cardiovascular disease; AAA wall calcification, degree of wall calcification at the maximal circumference of the abdominal aortic aneurysm.
finding of significantly reduced levels of the chemokine MCP-1 in AAA lesions from Mcpt6 Ϫ/Ϫ mice in comparison with WT mice ( Figure 2F ). Elastin fragmentation characterizes human or murine AAA. 24 Although elastin fragmentation increased over time in WT mice, it did not in Mcpt6 Ϫ/Ϫ mice. At 56 days postperfusion, aortas from WT mice showed more elastin fragmentation than did those from Mcpt6 Ϫ/Ϫ mice (Online Figure IA) .
We have previously shown that MCs participate in AAA formation by promoting aortic SMC apoptosis. 18 Ϫ/Ϫ mice at the same time point (Figure 2D ), suggesting that most of these medial apoptotic cells were SMC, as previously described in human AAA lesions. 25 The 2 genotypes did not have significant differences in lesion cell apoptosis or SMC content at the 14-day or 56-day time points (Figure 2D and Online Figure IB) .
Tryptase can stimulate endothelial tube formation in vitro and promote angiogenesis, 26 mice at any time point tested (Online Figure ID) , suggesting a negligible role of mMCP-6 in angiogenesis in this AAA model. An in vitro aortic ring angiogenesis assay yielded similar observations. Bone marrow-derived MCs (BMMC) from WT mice or Mcpt6 Ϫ/Ϫ mice, used as angiogenic stimuli, showed similar microvessels sprouting from the aortic rings (data not shown).
Reduced AAA formation, lesion inflammatory cell infiltration, or cell apoptosis in Mcpt6 Ϫ/Ϫ mice did not result from less MC accumulation. Enumeration of CD117
ϩ MCs showed no significant differences between the genotypes from all 3 time points (Online Figure IE) Ϫ/Ϫ mice subsided at the 56-day time point (Figure 3B and 3C) . In contrast, BMMC from WT and Mcpt6 Ϫ/Ϫ mice behaved similarly in regulating CD31 ϩ microvessel growth in AAA lesions at both time points ( Figure 3D ).
MCs Interact With Inflammatory and Vascular Cells
The finding of reduced leukocytes in Mcpt6 Ϫ/Ϫ mouse AAA lesions suggested a role of mMCP-6 in leukocyte homing. To test this hypothesis in vitro, we first examined whether the absence of mMCP-6 affects MC chemokine and cytokine expression. Real-time polymerase chain reaction (RT-PCR) analysis showed no significant differences in TNF-␣, IL-6, Ϫ/Ϫ mice again showed no significant differences in promoting TNF-␣, IL-6, and MCP-1 expression in all aforesaid leukocytes (not shown). Yet, EC from WT mice expressed significantly higher levels of the cytokines TNF-␣ and IL-6, and the chemokines CXCL1/KC, CXCL2/ MIP-2 (macrophage inflammatory protein-2), and CXCL5/LIX after stimulation with degranulated BMMC from WT mice than did BMMC from Mcpt6 Ϫ/Ϫ mice ( Figure 4A ), a finding that agrees with the reduced leukocyte content of Mcpt6 Ϫ/Ϫ AAA lesions ( Figures 2B, 2C, 3B, and 3C) .
To test further whether the absence of mMCP-6 directly affected monocyte transmigration, we assayed transmigration through a collagen-coated Boyden chamber cell using monocytes from WT and Mcpt6 Ϫ/Ϫ mice. Monocytes from
Mcpt6
Ϫ/Ϫ mice transmigrated more slowly than did those from WT mice under different concentrations of the chemokine SDF-1␣ ( Figure 4B ). Reduced transmigration of monocytes from Mcpt6 Ϫ/Ϫ mice suggested altered protease expression. Although monocytes do not express tryptase, these cells are rich sources of cysteinyl cathepsins involved in leukocyte transmigration. 27, 28 Monocytes from Mcpt6 Ϫ/Ϫ mice expressed significantly less mRNA encoding in all tested cathepsins-including cathepsins B, S, L, and K-than did those from WT mice ( Figure 4C) , as determined by RT-PCR.
We have previously shown that MCs induce aortic SMC apoptosis. 18 This study revealed reduced AAA media cell apoptosis in Mcpt6 Ϫ/Ϫ mice (Online Figure IC) , with concurrent increase of lesion SMC content ( Figure 2D ). Therefore, mMCP-6 may promote SMC apoptosis. We used postdegranulation supernatants of BMMC from WT and Mcpt6 Ϫ/Ϫ mice to test this hypothesis. Live or degranulated WT BMMC enhanced PDTC-induced SMC apoptosis. 18 In contrast, the supernatants of degranulated mMCP-6 -deficient BMMC showed significantly reduced induction of aortic SMC apoptosis under the same conditions ( Figure 4D ), supporting the contribution of tryptase mMCP-6 in this process. 
Tryptase Deficiency Affects Cysteine Protease Cathepsin Expression and Activities
Cysteine protease cathepsins and MMPs contribute to aortic wall remodeling. Mice lacking cysteine proteases-such as cathepsins S, K, or L-resist diet-induced atherosclerosis, [27] [28] [29] and MMP-9 -deficient, MMP-2-deficient, or chymase mMCP-4 -deficient mice show reduced experimental AAA formation. 30 -32 As discussed, MC tryptase participates in MMP and serine protease activation, 11, 12 processes pertinent to AAA formation. Absence of mMCP-6 may affect the expression or activation of these proteases in MCs, thereby providing an additional mechanism underlying reduced AAA formation in Mcpt6 Ϫ/Ϫ mice. BMMC from Mcpt6 Ϫ/Ϫ mice expressed significantly less mRNA encoding of cathepsins B, S, L, and K, but did not affect the expression of serine proteases cathepsin G, chymase mMCP-4, MMP-2, and MMP-9 mRNAs, as assessed by RT-PCR ( Figure 5A ). To test whether reduced cathepsin mRNA levels corresponded to altered enzymatic activities, we performed active site labeling for cysteine proteases with biotinylated JPM. BMMC cell lysates from Mcpt6 Ϫ/Ϫ mice showed reduced cathepsin activities, in comparison with those from WT mice ( Figure 5B ).
AAA lesions from Mcpt6
Ϫ/Ϫ mice also had reduced activities of cysteinyl cathepsins. Using frozen AAA sections and fluorescein-conjugated elastin as substrate, we performed in situ cathepsin zymography in a buffer that was optimized for cysteine protease cathepsin activities (pH 5.5). 18 AAA lesions from WT mice 56 days postperfusion showed elastolytic activity in the adventitia (green fluorescence), sensitive to the nonselective cathepsin inhibitor E64d (20 mol/L, Sigma-Aldrich, St. Louis, MO). In contrast, the adventitia in AAA sections from Mcpt6 Ϫ/Ϫ mice 56 days postperfusion contained much less elastolytic activity (green fluorescence), and E64d days showed negligible effect on this activity ( Figure  5C ), a finding consistent with reduced cathepsin activities in AAA lesions from Mcpt6 Ϫ/Ϫ mice. Although in situ cathepsin zymography experimental and photograph shuttering conditions were the same between AAA lesions from WT and Mcpt6 Ϫ/Ϫ mice, media green fluorescence was brighter in WT mice than in Mcpt6 Ϫ/Ϫ mice ( Figure 5C ), likely from increased media inflammatory cells in WT AAA lesions ( Figure 1D ). To confirm increased cathepsin activities in AAA lesions from WT mice in comparison with those from Mcpt6 Ϫ/Ϫ mice, we performed cysteinyl cathepsin active site labeling with JPM using AAA tissue extracts.
AAA tissue lysates from Mcpt6
Ϫ/Ϫ mice had reduced cathepsin activities in comparison with those from WT mice 56 days postperfusion ( Figure 5D ), consistent with less medial elastin degradation in AAA lesions from Mcpt6 Ϫ/Ϫ mice than in those from WT mice at this time point (Online Figure IA) .
Discussion
The release of undefined granular content from activated MCs contributes to arterial remodeling. 18, 33 The granules in mouse and human MCs contain substantial amounts of different types of neutral proteases. In particular, the chymase and tryptase families of MC-restricted serine proteases participate in pathological events, such as atherosclerosis, 34 that pertain to AAA pathogenesis. We have previously shown that the chymase mMCP-4 contributes to AAA by affecting lesion leukocyte infiltration, apoptosis, elastin degradation, and angiogenesis. 31 The absence of mMCP-4 (but not its chromosome 14C3 family member mMCP-5) protected mice from elastase perfusion-induced AAA. We now show that the chromosome 17A3.3 tryptase family member mMCP-6 also contributes critically to experimental AAA formation in mice, and biomarker studies also implicate this protease in human AAA.
Identifying novel biomarkers to predict arterial expansion-not only for the aorta but also for the coronary, cerebral, and peripheral arteries-could prove useful as an investigative tool and as a clinical tool. This study showed that human serum tryptase levels correlated significantly but weakly with the aneurysmal expansion rate (Pϭ0.005, Rϭ0.29) (Figure 1A) , suggesting that serum tryptase is probably not useful as a stand-alone biomarker in clinical decision making. Larger and broader clinical studies in the future, however, may yield different conclusions. Statistical significances and high Exp(B) values before and after adjusting for all available risk factors in predicting AAA expansion and subsequent aortic surgery and mortality in this small patient population follow-up study (Tables 3 and 4) , and the independence from traditional AAA risk factors, make this protease a compelling and attractive biomarker candidate. The present data suggest that both tryptase and chymase participate in mouse AAA development. Our prior study demonstrated that serum chymase levels also correlated with AAA expansion rate, 31 but not with the need for surgical repair or with death (not shown), which suggests that there are mechanistic differences between the 2 types of MC proteases. For example, BMMC from Mcpt4 Ϫ/Ϫ mice showed impaired activity in promoting microvessel growth in an aortic ring assay, and AAA lesions from Mcpt4 Ϫ/Ϫ mice had reduced CD31
ϩ microvessels compared with those in WT mouse AAA lesions. 31 Although tryptase may participate in angiogenesis, 26 we did not find an effect of this protease in promoting microvessel growth in the aortic ring assay (data not shown), and we did not detect significant differences in CD31-positive microvessel numbers in AAA lesions from WT mice and Mcpt6 Ϫ/Ϫ mice (Online Figure ID) . MC tryptase therefore may not influence angiogenesis in this AAA preparation.
This study suggests that tryptase regulates leukocyte recruitment to lesions in experimental AAA. AAA lesions from We have long been interested in why the absence of one protease affects the expression or activities of the others. All tested cathepsins showed lower expression in BMMC from Mcpt6 Ϫ/Ϫ mice than in those from WT mice ( Figure 5A and 5B). Although not tested in this study, tryptase is known to induce mitogen-activated protein kinase (MAPK) activation in human eosinophils. Phosphorylation of extracellular signal-regulated kinase-1 and -2 (ERK1/2), MAPK p38, and Jun N-terminal kinase-1 and -2 (JNK1/2) occur within 3 minutes after incubation with 50 ng/mL of recombinant human skin tryptase. 35 Conditional activation of ERK can induce the expression of CatB and CatL in 3T3 and K1735 cells. 36 The receptor activator of NF-B ligand (RANKL)-induced CatK expression during osteoclastogenesis depends on p38 MAPK. 37 The N-terminal telopeptide of collagen type II enhances expression of cathepsins B, K, and L in articular chondrocytes, and also associates with the activation of p38 MAPK. 38 Tryptase may control cathepsin expression in BMMC ( Figure 5A ) and in other inflammatory cells and vascular cells by regulating MAPK activation. This study tested whether reduced cathepsins in tryptase-deficient MCs resulted from decreased chymase expression. Although BMMC from Mcpt6 Ϫ/Ϫ mice expressed less mMCP-4 than did those from WT mice, this difference did not reach statistical significance. Cathepsin activities fell not only in MCs, but also in AAA lesions from Mcpt6 Ϫ/Ϫ mice. Reduced cathepsin expression and activity may result in part from fewer leukocytes in AAA lesions; leukocytes are a rich source of proteases and inflammatory stimuli that are required for vascular cell protease expression. 39, 40 The low MHC class II levels in Mcpt6-/-mouse lesions support this possibility ( Figure 2E ). Reduced cathepsin expression and activity in Mcpt6 Ϫ/Ϫ mice BMMC and aortic tissue extracts ( Figure 5 ) did not explain fully the aortic wall elastin fragmentation. Increased T-cell content at 7 days postperfusion and increased macrophage content after 14 days in WT mice relative to Mcpt6 Ϫ/Ϫ mice did not affect elastin degradation grades. Indeed, Mcpt6 Ϫ/Ϫ mice showed more elastin degradation than did WT mice at the 7-day time point (Online Figure IA) . We currently lack a good explanation for this finding, although absence of tryptase may lead to compensatory increase of other elastases at this time point, and this speculation merits further investigation. This study also demonstrated that the absence of mMCP-6 affects monocyte cathepsin expression ( Figure 4C ). This finding is perplexing, because mMCP-6 is a MC-specific protease and should not affect monocyte gene expression. These monocytes, isolated from peripheral blood, may have encountered a different environment. In humans, blood tryptase level (Ϸ100 ng/mL) is Ϸ10-fold that of chymase (Ϸ10 ng/mL), 31 20-fold that of cathepsin S (Ϸ5 ng/mL), 41 and Ͼ20-fold that of cathepsin L (Ͻ5 ng/mL). 42 A high blood tryptase level may affect blood cells, such as monocyte gene expression. Indeed, tryptase promotes human EC MCP-1 and IL-8 expression. 43 This study demonstrated that tryptase stimulated mouse EC expressions of IL6, KC, MIP-2, and LIX ( Figure 4A ). Tryptase in blood, therefore, may have more complex functions than previously appreciated.
Reduced apoptosis and enhanced SMC content in AAA lesions from Mcpt6 -/-mice at the 7-day time point suggested that tryptase could promote SMC apoptosis ( Figure 2D , Online Figure IB and IC) . Study of cultured SMC affirmed this hypothesis ( Figure 4D ). At later time points (14 days and 56 days postperfusion), however, tryptase expression did not affect AAA lesion SMC loss and apoptosis. Our current data do not explain these discrepant changes. As discussed, tryptase induces cysteinyl cathepsin expression via the MAPK pathway. [35] [36] [37] [38] These cathepsins induce cell apoptosis by cleaving the antiapoptotic protein Bcl-2 member Bid and creating a proapoptotic signal for mitochondrial cytochrome C release. 44 Observations in several cathepsin mutant mouse cells support this hypothesis, 45, 46 but tryptase inhibits Fas-induced fibroblast apoptosis in a concentrationdependent manner, likely via the Rho kinase pathway. 47 One mechanism may predominate over the other at different stages of AAA progression; this speculation requires experimental confirmation.
This study provided evidence from human AAA patients and mice with experimental AAA supporting the direct participation of MC tryptase in AAA pathogenesis. Although more mechanisms remain undiscovered, tryptase regulates EC cytokine and chemokine expression, leukocyte migration, SMC apoptosis, and AAA-pertinent cysteinyl cathepsin expression in lesions. All of these functions may contribute to AAA formation. Significant correlation of serum tryptase levels with subsequent surgery and overall mortality indicate that serum tryptase could serve as a biomarker of AAA expansion, and that pharmacological inhibition of tryptase activity might benefit AAA patients.
